HF 3880

02/24/26   REVISOR  SGS/RC  26-07113
This Document can be made available
in alternative formats upon request  State of Minnesota
  HOUSE OF REPRESENTATIVES
  NINETY-FOURTH SESSION
  H. F. No.   3880
03/02/2026     Authored by Lee, F.,
  The bill was read for the first time and referred to the Committee on Health Finance and Policy
1.1A bill for an act
1.2relating to health; establishing requirements for education and training on vaccine
1.3administration to prevent shoulder injuries related to vaccine administration;
1.4appropriating money; amending Minnesota Statutes 2024, sections 150A.055,
1.5subdivision 2; 151.01, subdivision 27; proposing coding for new law in Minnesota
1.6Statutes, chapter 145.
1.7BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.8Section 1. [145.676] SIRVA PREVENTION ACTIVITIES.
1.9Subdivision 1. Definition. For purposes of this section, "shoulder injury related to vaccine
1.10administration" or "SIRVA" has the meaning given in Code of Federal Regulations, title
1.1142, section 100.3(c)(10).
1.12Subd. 2. SIRVA prevention poster. All health clinics, pharmacies, and other health
1.13care settings where vaccines are administered must display a poster created or approved by
1.14the commissioner of health that describes proper vaccine administration techniques to
1.15prevent shoulder injury related to vaccine administration. The poster must be displayed at
1.16one or more locations in the clinic, pharmacy, or health care setting where the poster is
1.17visible to the public and all health care personnel authorized to administer vaccines at the
1.18clinic, pharmacy, or health care setting.
1.19Subd. 3. Training. In order to administer vaccines on or after July 1, 2026, health care
1.20personnel otherwise authorized to administer vaccines must complete comprehensive,
1.21competency-based training on vaccine administration. The training must conform with the
1.22guidance of the Centers for Disease Control and Prevention on vaccine administration and
1.23must at least address vaccine preparation, proper needle selection, site and route selection,
1.24administration, and SIRVA as a potentially serious complication resulting from improper
Section 1.  1
02/24/26   REVISOR  SGS/RC  26-07113
2.1  vaccine administration. After completing the training, health care personnel must submit
2.2  evidence of completion to the health-related licensing board that regulates the health care
2.3  personnel.
2.4      Subd. 4. Exceptions. This section does not apply to veterinary clinics, veterinary
2.5  hospitals, licensed veterinarians, or licensed veterinary technicians.
2.6    Sec. 2. Minnesota Statutes 2024, section 150A.055, subdivision 2, is amended to read:
2.7      Subd. 2. Qualified dentists. (a) The vaccine shall be administered only to eligible
2.8  patients 16 years of age and older and only by licensed dentists who:
2.9      (1) have immediate access to emergency response equipment, including but not limited
2.10 to oxygen administration equipment, epinephrine, and other allergic reaction response
2.11 equipment; and
2.12     (2) are trained in or have successfully completed an educational program on vaccine
2.13 administration that is approved by the Minnesota Board of Dentistry, specifically for the
2.14 administration of vaccines. The training or program must comply with the requirements in
2.15 section 145.676, subdivision 3, and must include:
2.16     (i) educational material on the disease and vaccination as prevention of the disease;
2.17     (ii) contraindications and precautions;
2.18     (iii) intramuscular administration;
2.19     (iv) communication of risk and benefits of vaccination and legal requirements involved;
2.20     (v) reporting of adverse events;
2.21     (vi) documentation required by federal law; and
2.22     (vii) storage and handling of vaccines.
2.23     (b) Any dentist giving vaccinations under this section shall comply with guidelines
2.24 established by the federal Advisory Committee on Immunization Practices relating to
2.25 vaccines and immunizations, which includes, but is not limited to, vaccine storage and
2.26 handling, vaccine administration and documentation, and vaccine contraindications and
2.27 precautions.
2.28   Sec. 3. Minnesota Statutes 2024, section 151.01, subdivision 27, is amended to read:
2.29     Subd. 27. Practice of pharmacy. "Practice of pharmacy" means:
2.30     (1) interpretation and evaluation of prescription drug orders;
Sec. 3.  2
02/24/26   REVISOR  SGS/RC  26-07113
3.1      (2) compounding, labeling, and dispensing drugs and devices (except labeling by a
3.2  manufacturer or packager of nonprescription drugs or commercially packaged legend drugs
3.3  and devices);
3.4      (3) participation in clinical interpretations and monitoring of drug therapy for assurance
3.5  of safe and effective use of drugs, including ordering and performing laboratory tests that
3.6  are waived under the federal Clinical Laboratory Improvement Act of 1988, United States
3.7  Code, title 42, section 263a et seq. A pharmacist may collect specimens, interpret results,
3.8  notify the patient of results, and refer the patient to other health care providers for follow-up
3.9  care and may initiate, modify, or discontinue drug therapy only pursuant to a protocol or
3.10 collaborative practice agreement. A pharmacist may delegate the authority to administer
3.11 tests under this clause to a pharmacy technician or pharmacy intern. A pharmacy technician
3.12 or pharmacy intern may perform tests authorized under this clause if the technician or intern
3.13 is working under the direct supervision of a pharmacist;
3.14     (4) participation in drug and therapeutic device selection; drug administration for first
3.15 dosage and medical emergencies; intramuscular and subcutaneous drug administration under
3.16 a prescription drug order; drug regimen reviews; and drug or drug-related research;
3.17     (5) drug administration, through intramuscular and subcutaneous administration used
3.18 to treat mental illnesses as permitted under the following conditions:
3.19     (i) upon the order of a prescriber and the prescriber is notified after administration is
3.20 complete; or
3.21     (ii) pursuant to a protocol or collaborative practice agreement as defined by section
3.22 151.01, subdivisions 27b and 27c, and participation in the initiation, management,
3.23 modification, administration, and discontinuation of drug therapy is according to the protocol
3.24 or collaborative practice agreement between the pharmacist and a dentist, optometrist,
3.25 physician, physician assistant, podiatrist, or veterinarian, or an advanced practice registered
3.26 nurse authorized to prescribe, dispense, and administer under section 148.235. Any changes
3.27 in drug therapy or medication administration made pursuant to a protocol or collaborative
3.28 practice agreement must be documented by the pharmacist in the patient's medical record
3.29 or reported by the pharmacist to a practitioner responsible for the patient's care;
3.30     (6) initiating, ordering, and administering influenza and COVID-19 or SARS-CoV-2
3.31 vaccines authorized or approved by the United States Food and Drug Administration to all
3.32 eligible individuals three years of age and older and all other United States Food and Drug
3.33 Administration-approved vaccines to patients six years of age and older according to the
3.34 federal Advisory Committee on Immunization Practices recommendations. A pharmacist
Sec. 3.  3
02/24/26   REVISOR  SGS/RC  26-07113
4.1  administering vaccines under this clause must have completed training that complies with
4.2  the requirements in section 145.676, subdivision 3. A pharmacist may delegate the authority
4.3  to administer vaccines under this clause to a pharmacy technician or pharmacy intern who
4.4  has completed training in vaccine administration that complies with the requirements in
4.5  section 145.676, subdivision 3, if:
4.6      (i) the pharmacist and the pharmacy technician or pharmacy intern have successfully
4.7  completed a program approved by the Accreditation Council for Pharmacy Education
4.8  (ACPE) specifically for the administration of immunizations or a program approved by the
4.9  board;
4.10     (ii) the pharmacist utilizes the Minnesota Immunization Information Connection to
4.11 assess the immunization status of individuals prior to the administration of vaccines, except
4.12 when administering influenza vaccines to individuals age nine and older;
4.13     (iii) the pharmacist reports the administration of the immunization to the Minnesota
4.14 Immunization Information Connection;
4.15     (iv) if the patient is 18 years of age or younger, the pharmacist, pharmacy technician,
4.16 or pharmacy intern informs the patient and any adult caregiver accompanying the patient
4.17 of the importance of a well-child visit with a pediatrician or other licensed primary care
4.18 provider; and
4.19     (v) in the case of a pharmacy technician administering vaccinations while being
4.20 supervised by a licensed pharmacist:
4.21     (A) the supervision is in-person and must not be done through telehealth as defined
4.22 under section 62A.673, subdivision 2;
4.23     (B) the pharmacist is readily and immediately available to the immunizing pharmacy
4.24 technician;
4.25     (C) the pharmacy technician has a current certificate in basic cardiopulmonary
4.26 resuscitation;
4.27     (D) the pharmacy technician has completed a minimum of two hours of ACPE-approved,
4.28 immunization-related continuing pharmacy education as part of the pharmacy technician's
4.29 two-year continuing education schedule; and
4.30     (E) the pharmacy technician has completed one of two training programs listed under
4.31 Minnesota Rules, part 6800.3850, subpart 1h, item B;
Sec. 3.  4
02/24/26   REVISOR  SGS/RC  26-07113
5.1      (7) participation in the initiation, management, modification, and discontinuation of
5.2  drug therapy according to a written protocol or collaborative practice agreement between:
5.3  (i) one or more pharmacists and one or more dentists, optometrists, physicians, physician
5.4  assistants, podiatrists, or veterinarians; or (ii) one or more pharmacists and one or more
5.5  physician assistants authorized to prescribe, dispense, and administer under chapter 147A,
5.6  or advanced practice registered nurses authorized to prescribe, dispense, and administer
5.7  under section 148.235. Any changes in drug therapy made pursuant to a protocol or
5.8  collaborative practice agreement must be documented by the pharmacist in the patient's
5.9  medical record or reported by the pharmacist to a practitioner responsible for the patient's
5.10 care;
5.11     (8) participation in the storage of drugs and the maintenance of records;
5.12     (9) patient counseling on therapeutic values, content, hazards, and uses of drugs and
5.13 devices;
5.14     (10) offering or performing those acts, services, operations, or transactions necessary
5.15 in the conduct, operation, management, and control of a pharmacy;
5.16     (11) participation in the initiation, management, modification, and discontinuation of
5.17 therapy with opiate antagonists, as defined in section 604A.04, subdivision 1, pursuant to:
5.18     (i) a written protocol as allowed under clause (7); or
5.19     (ii) a written protocol with a community health board medical consultant or a practitioner
5.20 designated by the commissioner of health, as allowed under section 151.37, subdivision 13;
5.21     (12) prescribing self-administered hormonal contraceptives; nicotine replacement
5.22 medications; and opiate antagonists for the treatment of an acute opiate overdose pursuant
5.23 to section 151.37, subdivision 14, 15, or 16;
5.24     (13) participation in the placement of drug monitoring devices according to a prescription,
5.25 protocol, or collaborative practice agreement;
5.26     (14) prescribing, dispensing, and administering drugs for preventing the acquisition of
5.27 human immunodeficiency virus (HIV) if the pharmacist meets the requirements in section
5.28 151.37, subdivision 17; and
5.29     (15) ordering, conducting, and interpreting laboratory tests necessary for therapies that
5.30 use drugs for preventing the acquisition of HIV, if the pharmacist meets the requirements
5.31 in section 151.37, subdivision 17.
Sec. 3.  5
      02/24/26   REVISOR  SGS/RC  26-07113
6.1   Sec. 4. APPROPRIATION; SIRVA PREVENTION POSTER.
6.2     $....... in fiscal year 2027 is appropriated from the general fund to the commissioner of
6.3 health to:
6.4     (1) create or approve a poster to educate health care personnel and the public about
6.5 proper vaccine administration techniques to prevent shoulder injury related to vaccine
6.6 administration (SIRVA); and
6.7     (2) make this poster available for display in all health care settings where vaccines are
6.8 administered.
6.9 This is a onetime appropriation.
      Sec. 4.  6